Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170032/S019

Woven EndoBridge Aneurysm Embolization (WEB) System

Microvention, Inc. · Decision date Mar 20, 2026

FDA DECISIONP170032/S019

What did the FDA approve?

FDA records P170032/S019 as a supplement to PMA P170032, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Mar 20, 2026.

FDA approval order statement

Approval of the revised protocol for the PAS1 PostMarket Surveillance-Long Term Safety post-approval study.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Neurology
Decision date
Mar 20, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P170032/S019
Regulatory pathway
PMA supplement
Product code
OPR
Decision code
APPR
Decision date
Mar 20, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Intrasaccular Flow Disruption Device.

Product code
OPR
FDA device class
3

For the original device and its historical approval scope, see PMA P170032. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P170032 · Original PMA

    Woven EndoBridge (WEB) Aneurysm Embolization System

  2. P170032/S019 received

    Application receipt date recorded by FDA.

  3. P170032/S019 · FDA decision

    Normal 180 Day Track No User Fee

  4. P170032/S021 · Related supplement

    Woven EndoBridge (WEB) Aneurysm Embolization System

  5. P170032/S022 · Related supplement

    Woven EndoBridge (WEB) Aneurysm Embolization System

  6. P170032/S024 · Related supplement

    Woven EndoBridge (WEB) Aneurysm Embolization System

Timeline entries are records held by MedtechLedger for P170032. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170032

Product / regulatory recordCompanyPathwayDecision dateSource
Microvention, Inc.PMA approvalDec 31, 2018FDA
Microvention, Inc.PMA supplementMay 1, 2026FDA
Microvention, Inc.PMA supplementMay 28, 2026FDA
Microvention, Inc.PMA supplementOct 27, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Microvention, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
35 Enterprise, Aliso Viejo, CA, 92656

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records